Recent advances in the management of ovarian cancer include:
1) Optimal treatment of early-stage disease involves debulking surgery followed by carboplatin and paclitaxel chemotherapy based on trials showing improved recurrence-free and overall survival.
2) Maintenance therapy with bevacizumab or PARP inhibitors prolongs progression-free survival and overall survival compared to placebo in recurrent platinum-sensitive disease.
3) The role of secondary cytoreductive surgery and intraperitoneal chemotherapy in recurrent disease continues to be evaluated in ongoing clinical trials.
Join Dr. Kara Long Roche, Associate Director of the Gynecologic Oncology Fellowship Program at Memorial Sloan Kettering Cancer Center, as she breaks down new advancements in ovarian cancer research and treatment.
Join Dr. Kara Long Roche, Associate Director of the Gynecologic Oncology Fellowship Program at Memorial Sloan Kettering Cancer Center, as she breaks down new advancements in ovarian cancer research and treatment.
Hitting the Target in HER2-Positive Metastatic Colorectal Canceri3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck will share the latest data and strategies for hitting the target in HER2-positive metastatic colorectal cancer. Dr. Christopher Lieu, Associate Professor at the University of Colorado Cancer Center, explores actionable targets to inform personalized care plans, guideline-recommended combination and sequencing strategies, adverse event monitoring and management, and more.
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatments targeting HER2 are some of the most recent additions to the arsenal of targeted therapy for this disease. This activity chaired by Christopher Lieu, MD, Associate Director of Clinical Research at the University of Colorado Cancer Center, will provide expert perspectives and practical guidance on treating HER2-positive metastatic CRC.
TARGET AUDIENCE
Oncologists, gastroenterologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with colorectal cancer (CRC).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
Distinguish actionable targets that can inform personalized care plans in metastatic CRC
Evaluate practice guidelines on treatment combinations and sequences for patients with metastatic CRC
Appraise emerging efficacy and safety data on novel targeted therapies for patients with HER2-positive metastatic CRC
Assess strategies for optimizing the safety and tolerability of novel targeted therapies for HER2-positive metastatic CRC
Tonight’s speakers: Dr. Dan Sargent and Kim Ryan
Disclaimer: “This Report is not an official event of the 2012 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2012 Gastrointestinal Cancers Symposium.”
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Pharma Intelligence
In conjunction with a Key Opinion Leader, Dr. Peter Lee MD Chair, Department of Immuno-Oncology at City of Hope Comprehensive Cancer Center, CA, several Informa analysts discuss the major developments of the conference and key take-aways via a Webinar.
Watch our recording of Biomedtracker's Robert Jeng, Ph,D., Citeline's Allison Bruce, Scrip's Mary Jo Laffler, and Datamonitor Healthcare's Zachary McLellan as they download and debrief following the always-exciting ASCO weekend.
View and listen to the full webinar here https://www.youtube.com/watch?v=7yMsCb3R5X8
Pr Olivier Glehen (Lyon - France) presents HIPEC in treatment for colorectal and gastric carcinomatosis. La CHIP dans le traitement des carcinoses péritonéales d'origine colorectale et gastrique.
nside Myriad. At Myriad, our goal is to make a difference in patients' lives and our work has been guided by this mission throughout the Company's history. ... Since 1991, Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
Has cancer science got you stumped and overwhelmed? Leading gynecologic oncologist, Dr. Don Dizon, takes us to cancer college in this webinar. He explains the science behind ovarian cancer, how it develops, how it's diagnosed, and how ovarian cancer treatments work.
Recurrent Ca Endometrium Vaginal Interstitial.pptxSadia Sadiq
a case of recurrent endometrial cancer with vaginal involvement where free hand needle placement resulted in adequate target coverage and excellent response.
Hitting the Target in HER2-Positive Metastatic Colorectal Canceri3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck will share the latest data and strategies for hitting the target in HER2-positive metastatic colorectal cancer. Dr. Christopher Lieu, Associate Professor at the University of Colorado Cancer Center, explores actionable targets to inform personalized care plans, guideline-recommended combination and sequencing strategies, adverse event monitoring and management, and more.
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatments targeting HER2 are some of the most recent additions to the arsenal of targeted therapy for this disease. This activity chaired by Christopher Lieu, MD, Associate Director of Clinical Research at the University of Colorado Cancer Center, will provide expert perspectives and practical guidance on treating HER2-positive metastatic CRC.
TARGET AUDIENCE
Oncologists, gastroenterologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with colorectal cancer (CRC).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
Distinguish actionable targets that can inform personalized care plans in metastatic CRC
Evaluate practice guidelines on treatment combinations and sequences for patients with metastatic CRC
Appraise emerging efficacy and safety data on novel targeted therapies for patients with HER2-positive metastatic CRC
Assess strategies for optimizing the safety and tolerability of novel targeted therapies for HER2-positive metastatic CRC
Tonight’s speakers: Dr. Dan Sargent and Kim Ryan
Disclaimer: “This Report is not an official event of the 2012 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2012 Gastrointestinal Cancers Symposium.”
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Pharma Intelligence
In conjunction with a Key Opinion Leader, Dr. Peter Lee MD Chair, Department of Immuno-Oncology at City of Hope Comprehensive Cancer Center, CA, several Informa analysts discuss the major developments of the conference and key take-aways via a Webinar.
Watch our recording of Biomedtracker's Robert Jeng, Ph,D., Citeline's Allison Bruce, Scrip's Mary Jo Laffler, and Datamonitor Healthcare's Zachary McLellan as they download and debrief following the always-exciting ASCO weekend.
View and listen to the full webinar here https://www.youtube.com/watch?v=7yMsCb3R5X8
Pr Olivier Glehen (Lyon - France) presents HIPEC in treatment for colorectal and gastric carcinomatosis. La CHIP dans le traitement des carcinoses péritonéales d'origine colorectale et gastrique.
nside Myriad. At Myriad, our goal is to make a difference in patients' lives and our work has been guided by this mission throughout the Company's history. ... Since 1991, Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
Has cancer science got you stumped and overwhelmed? Leading gynecologic oncologist, Dr. Don Dizon, takes us to cancer college in this webinar. He explains the science behind ovarian cancer, how it develops, how it's diagnosed, and how ovarian cancer treatments work.
Recurrent Ca Endometrium Vaginal Interstitial.pptxSadia Sadiq
a case of recurrent endometrial cancer with vaginal involvement where free hand needle placement resulted in adequate target coverage and excellent response.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
3. • Approximately 314 000 new ovarian cancer cases and 207 000 deaths
occurred in 2020.
• There were marked geographic variations in incidence rates, with the
highest rates observed in European countries with very high HDI and
low rates were found in African countries within the lowest HDI
group.
4. • Relative to 2020 estimates, our projection for 2040 indicates
approximately 96% and 100% increase in new ovarian cancer cases
and deaths, respectively, among low HDI countries compared to 19%
and 28% in very high HDI countries.
13. DESKTOP III - BACKGROUND
• Role of secondary cytoreductive surgery not fully defined for recurrent ovarian
cancer through prospectively randomized trials
• DESKTOP I and II trials developed, evaluated AGO Score metric to identify
patients with complete resection during secondary cytoreductive surgery
• AGO Score based on good ECOG PS (0), complete resection during first-line therapy,
ascites < 500 mL
• Positive AGO Score predicted complete resection with 95% probability
DESKTOP III trial was designed to evaluate survival benefit of secondary
cytoreductive surgery in selected patients with platinum-sensitive recurrent
ovarian cancer
21. BRCA Mutations and Ovarian Cancer
• BRCA genes encode enzymes
that repair double-strand DNA
breaks
• Mutations in BRCA1 or BRCA2
• Prognostic marker for increased
risk of ovarian cancer
• Prognostic marker for increased
survival
• Predictive marker for enhanced
PARP inhibitor activity
Risk of Developing Ovarian Cancer
Mutated BRCA1
39% to 46%
Mutated BRCA2
10% to 27%
Normal BRCA
2%
Slide credit: clinicaloptions.com
https://www.acog.org/Patients/FAQs/BRCA1-and-BRCA2-Mutations
22.
23. HRD and BRCA Mutations
Germline BRCA
mutations
Germline non-BRCA
mutations in HR pathway
Sporadic (somatic) BRCA
mutations
Sporadic non-BRCA
mutations in HR pathway
Mutations in HR pathway
↓
HRD
Slide credit: clinicaloptions.com
25. Current Treatment Landscape for PARPi in Ovarian
Cancer
Slide credit: clinicaloptions.com
Under investigation
FDA approved
y
Symptoms
Diagnosis
Chemo
#1
Staging/debulking
Evaluation
Progression
Chemo
#2
Chemo
#3
T
Supportive
care
Death
Chemo
#4+
T
Maintenance M M
Concomitant Concomitant
LaFargue. Lancet Oncol. 2019;20:e15.
26. PARP Inhibitors: Current Indications
Slide credit: clinicaloptions.com
Olaparib PI 2018; Rucaparib PI 2018; Niraparib PI 2019.
27. PARP INHIBITORS:PHASE 3 TRIALS
PFS PFS (BRCAm)
Olaparib-1st line SOLO 1 3 y 60 % v 27 % same
Olaparib-pl.sen.
recurrence
SOLO 2 19.1 v 5.5 months same
Niraparib-pl. sen.
recurrence
NOVA NR Median 21 v 5.5
months
Rucaparib-pl.sen.
recurrence
ARIEL 3 10.8 v 5.4 months 16.6 v 5.4 months
28. PAOLA-1 Phase III Trial: Final
Overall Survival Results of Maintenance
Olaparib + Bevacizumab in Patients With
Newly Diagnosed Advanced Ovarian Cancer
Supported by educational grants from AstraZeneca; Bristol Myers Squibb;
Exelixis, Inc.; Gilead Sciences, Inc.; and Merck Sharp & Dohme Corp.
CCO Independent Conference Coverage*
of the ESMO 2022 Annual Congress; September 9-13, 2022; Paris, France
*CCO is an independent medical education company that provides state-of-the-art medical information to
healthcare professionals through conference coverage and other educational programs.
29.
30.
31. LYNPARZA + bevacizumab demonstrated a clinically
significant median PFS benefit of 3.9 years vs 1.5 years with
bevacizumab + placebo in HRD-positive patients
32. ROLE OF IMMUNOTHERAPY
• Immunotherapy has proved effective in a number of recurrent
cancers but has been less successful for patients with ovarian cancer.
• Pembrolizumab RR 10%
• Nivolumab as a single agent or combined with ipilimumab RR 30%
• Niraparib plus Pembro RR 18%
37. No significant advantage in progression-free or overall survival was observed in optimally
resected patients with stage III disease given either intraperitoneal chemotherapy regimen compared with
the intravenous-only arm after a median follow-up of 85 months.
The quality of life was best in the intravenous arm.
44. OVHIPEC-02
The objective of this study is to prove that treatment with primary cytoreductive surgery in combination
with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without
HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer
who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5
mm.
45. SEER registry of survival rates for ovarian cancer by stage and time since diagnosis
46. THANK YOU !
• Through ongoing advances, we hope that ovarian cancer will
transition from a historically highly fatal disease to a chronic
but treatable illness, and, increasingly, to one that is curable,